Webinar: Designing a Drug for COVID-19: Considerations for Inhaled Therapeutics to Treat Respiratory Diseases
The 2020 COVID-19 pandemic has brought into focus the devastating impact of lung diseases, with scientists around the world urgently seeking new therapies. Inhaled delivery of therapy can provide great advantages, including direct delivery to site of action, high local concentration in the lung and fast onset of action. If you’re considering an inhaled formulation, join us for valuable guidance on respiratory drug design.
Dry powders are the most common type of inhalation test item currently, but also some of the most problematic. In a powder, there are inter-particle forces between all the particles that determine how they will flow and ultimately aerosolize. This is critical to understand prior to the start of running an inhalation toxicology study. In this webinar, you will learn how determining physicochemical properties of powder test items can reduce aerosol generation variability and lead to more consistency in doses administered.